[Correspondence] Subclinical leaflet thrombosis
Tarun Chakravarty and colleagues (June 17, 2017, p 2383)1 reported that anticoagulation was superior to dual antiplatelet therapy in the prevention of subclinical valve thrombosis. This highly relevant analysis added much-needed evidence regarding optimal antithrombotic medication in patients with transcatheter aortic valve replacement. In these patients, ischaemic events are rare and bleeding events are frequent. Unfortunately, bleeding was not investigated and interindividual pharmacodynamic response to antiplatelet medication varies substantially.